Dimensional Fund Advisors LP Buys 183,881 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

Dimensional Fund Advisors LP lifted its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,604,876 shares of the company's stock after purchasing an additional 183,881 shares during the period. Dimensional Fund Advisors LP owned about 1.09% of Adaptive Biotechnologies worth $9,622,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Barclays PLC boosted its holdings in shares of Adaptive Biotechnologies by 149.5% in the third quarter. Barclays PLC now owns 230,177 shares of the company's stock valued at $1,180,000 after acquiring an additional 137,936 shares in the last quarter. GAMMA Investing LLC purchased a new stake in Adaptive Biotechnologies in the 4th quarter worth approximately $59,000. SG Americas Securities LLC boosted its position in shares of Adaptive Biotechnologies by 11.7% in the fourth quarter. SG Americas Securities LLC now owns 45,944 shares of the company's stock valued at $275,000 after acquiring an additional 4,799 shares during the period. Impact Partnership Wealth LLC grew its stake in Adaptive Biotechnologies by 8.8% during the fourth quarter. Impact Partnership Wealth LLC now owns 19,078 shares of the company's stock worth $114,000 after buying an additional 1,539 shares during the last quarter. Finally, KBC Group NV bought a new stake in Adaptive Biotechnologies in the fourth quarter valued at about $50,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 68,412 shares of Adaptive Biotechnologies stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $7.35, for a total value of $502,828.20. Following the completion of the sale, the insider now owns 1,279,524 shares in the company, valued at $9,404,501.40. The trade was a 5.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Francis Lo sold 20,875 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $6.99, for a total value of $145,916.25. Following the sale, the insider now owns 332,846 shares of the company's stock, valued at approximately $2,326,593.54. The trade was a 5.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 826,013 shares of company stock valued at $6,543,452 in the last ninety days. Insiders own 6.20% of the company's stock.

Wall Street Analysts Forecast Growth

ADPT has been the subject of several recent analyst reports. Piper Sandler restated an "overweight" rating and set a $13.00 target price (up from $11.00) on shares of Adaptive Biotechnologies in a research note on Tuesday, May 6th. Morgan Stanley raised their price target on Adaptive Biotechnologies from $7.00 to $9.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Scotiabank increased their price objective on Adaptive Biotechnologies from $10.00 to $12.00 and gave the company a "sector outperform" rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group increased their price objective on shares of Adaptive Biotechnologies from $9.00 to $10.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $9.83.

Adaptive Biotechnologies Stock Performance

ADPT traded down $0.22 on Tuesday, hitting $9.29. 1,021,800 shares of the company were exchanged, compared to its average volume of 1,583,364. Adaptive Biotechnologies Co. has a 12 month low of $2.99 and a 12 month high of $10.28. The stock has a market capitalization of $1.41 billion, a PE ratio of -8.52 and a beta of 1.75. The firm has a fifty day simple moving average of $7.89 and a two-hundred day simple moving average of $7.11.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.20) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.08. Adaptive Biotechnologies had a negative net margin of 89.12% and a negative return on equity of 64.65%. The company had revenue of $52.44 million during the quarter, compared to analysts' expectations of $42.13 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. Adaptive Biotechnologies's revenue for the quarter was up 25.2% compared to the same quarter last year. On average, equities analysts expect that Adaptive Biotechnologies Co. will post -0.92 earnings per share for the current year.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.